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Abstract
Background: Parkinson's disease (PD) involves the selective damage of dopaminergic neuron cells resulting from the 
accumulation and fibril formation of alpha-synuclein. Recently, it has been shown that not only full-length alpha-
synuclein, but also C-terminal truncated forms exist in the normal brain, as well as Lewy bodies, which are cytoplasmic 
inclusions in PD. It is known that truncated alpha-synuclein has a much higher ability to aggregate and fibrillate than 
full-length alpha-synuclein. Since the fibrils and precursor oligomers of alpha-synuclein are cytotoxic to the neuron, 
inhibitors that prevent the formation of oligomers and/or fibrils might open the way to a novel therapeutic approach 
to PD. However, no inhibitor for truncated alpha-synuclein has been reported yet.
Results: In this study, we first characterized the aggregation and cytotoxicity of C-truncated alpha-synuclein119 and 
alpha-synuclein133 which have been found in both the normal and the pathogenic brain. Alpha-synuclein119 
aggregated more rapidly and enhanced significantly the fibril formation of alpha-synuclein. Although both of alpha-
synuclein119 and alpha-synuclein133 showed a high cytotoxicity, alpha-synuclein133 showed a similar aggregation 
with full-length alpha-synuclein and no acceleration effect. We showed that PQQ dramatically inhibits the fibril 
formation of C-terminal truncated alpha-synuclein110119, and 133 as well as the mixtures of full-length alpha-
synuclein with these truncated variants. Moreover, PQQ decreases the cytotoxicity of truncated alpha-synuclein.
Conclusions: Our results demonstrate that PQQ inhibits the amyloid fibril formation and cytotoxicity of the C-
truncated alpha-synuclein variants. We believe that PQQ is a strong candidate for a reagent compound in the 
treatment of PD.
Background
Parkinson' disease (PD) is a common neurodegenerative
movement disorder affecting approximately 1% of the
population above 65 years of age; it is a progressive neu-
rodegenerative disease which develops slowly. The PD is
caused by the specific and progressive degeneration of
dopaminergic neurons in the substantia nigra. The neu-
rodegeneration is accompanied by the presence of cyto-
plasmic inclusions, termed Lewy bodies (LBs). These
inclusions are the hallmark pathological feature of PD [1-
4]. The hypothesis according to which α-synuclein (α-
Syn) plays a causative role in PD pathogenesis is strongly
supported, since the major fibrillar protein component of
LBs in both sporadic and familial PD is α-Syn, and three
different α-Syn missense mutations (A30P, A53T and
E46K) and the duplication and triplication of loci cause
autosomal-dominant PD [5-9]. Several in-vitro studies
have suggested that α-Syn's propensity to oligomerize and
form fibrils may play a crucial role in its toxicity [10,12].
Current treatments are only symptomatic and do not stop
or delay the progressive loss of neurons; there is as yet no
preventative therapy available for PD.
α-Synuclein (140 aa) is a natively unfolded protein that
is enriched in the presynaptic terminal of the neurons in
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Page 2 of 11the brain. The primary sequence of α-Syn is subdivided
into three regions: the amphiphatic N-terminal region
(residues 1-60), the highly hydrophobic central region
called "NAC" (61-95), and the acidic C-terminal region
(96-140) [13]. The C-terminal region is important for the
high thermostability of α-Syn and for the chaperon activ-
ity [14]. Moreover, the C-terminal region regulates the
amyloid aggregation and fibril formation of α-Syn. It is
known from patients suffering from α-synucleinopathy
that the C-terminal-truncated forms of α-Syn consist in
LBs [15-18]. Several in vitro studies have shown the pro-
pensity of α-Syn to aggregate into amyloid fibrils, a pro-
cess that is accelerated by the truncation of its C-
terminal. In addition, when full-length α-Syn is mixed
with C-terminal-truncated variants, the truncated α-Syn
accelerate the aggregation of the full-length protein
[17,19-21]. Recently, truncated α-Syn has been identified
in the normal brain [18]. This indicates that the trunca-
tion of the C-terminal of α-Syn has some relevance to the
pathogenesis of PD. Although many truncated variants
have been characterized, some of the truncated α-Syn
variants which exist in both the normal and the patho-
genic brain, such as α-Syn119 and α-Syn133, have not yet
been investigated through in vitro aggregation and fibril
formation studies.
Neurodegenerative diseases, such as Parkinson' disease,
Alzheimer's disease and prion disease, share the feature
that the causative proteins change their conformation
from the natural to the β-strand-rich conformation,
acquiring oligomeric status, and subsequently forming
supramolecular assemblies and amyloids. Considering
that the formation of amyloid fibrils as well as their pre-
cursor oligomers is cytotoxic, agents that prevent the for-
mation of the oligomers and/or fibrils might open the
way to a novel therapeutic approach to these neurode-
generative diseases [22]. Therefore, considerable effort
has been made to discover a molecule which prevents the
amyloid formation of the causative proteins in these dis-
eases, i.e., α-Syn [11,23], amyloid β [24,25] and prion pro-
tein [26], respectively.
Previously, we studied the amyloid fibril formation
mechanism of α-Syn and the development of a strategy
for its prevention [27]. Also, we have reported that the
antioxidant pyrroloquinoline quinone (PQQ) (Fig. 1),
which is a noncovalently bound bacterial cofactor in the
oxidative metabolism of alcohols, prevents the amyloid
fibril formation and aggregation of full-length α-Syn in
vitro in a PQQ-concentration-dependent manner [28].
PQQ forms a conjugate with WT α-Syn, and this PQQ-
conjugated α-Syn is also able to prevent α-Syn amyloid
fibril formation. The fact that PQQ shows anti-fibril-
forming activity for α-Syn and other amyloid proteins and
has never been reported, nor has a molecule which is able
to prevent the amyloid formation of truncated α-Syn ever
been described; this encouraged us to further investigate
the effects of PQQ on the fibrillization and cytotoxicity of
C-terminal-truncated α-Syn.
In this study, we first characterized the aggregation and
fibrillation of truncated α-Syn119 and 133 as well as mix-
tures of full-length α-Syn with these truncated variants.
We were able to demonstrate that PQQ dramatically
inhibits the fibril formation of C-terminal-truncated α-
Syn110, α-Syn119, and α-Syn133. Moreover, PQQ
decreased the cytotoxicity of the truncated variants. Our
results suggest PQQ has a strong potential as a relevant
leading compound in the design of new amyloid inhibi-
tors.
Results
Effect of truncation on the aggregation and fibril formation 
of α-synuclein
The binding of TfT to protein fibrils is accompanied by a
characteristic increase in fluorescence intensity in the
vicinity of 482 nm. (Fig. 2) compares the fibril formation
patterns of full-length and truncated α-Syn110, α-Syn119,
and α-Syn133, as monitored by TfT fluorescence. In
agreement with earlier studies, the truncated α-Syn110
showed a much faster rate of fibril formation than full-
length α-Syn. Also the fibril formation of truncated α-
Syn119 was faster than that of full-length α-Syn. Mean-
while, the fibril formation of truncated α-Syn133 was
slower than that of full-length α-Syn. The maximal values
of fluorescence intensity in truncated α-Syn110, α-
Syn119, and α-Syn133 were 3, 1.5 and 0.6-fold of full-
length α-Syn and the lag time of truncated α-Syn was 4.8,
14.3 and 36.1 h respectively (full-length α-Syn, 21.4 h).
Figure 1 Structure of pyrroloquinoline quinone.
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Page 3 of 11The light scattering from protein solutions reflects the
quantity of aggregates; i.e., this contained large soluble
oligomers, amorphous aggregates and amyloid fibrils.
The light scattering study showed that the aggregation
ability of truncated α-Syn110 was higher than that of full-
length α-Syn, but that the aggregation ability of truncated
α-Syn119 and α-Syn133 was at same level as that of the
full-length protein (Fig. 3).
Truncated α-synuclein enhanced the fibril formation of α-
synucleins
These truncated variants co-exist with full-length α-Syn
in both the normal and the pathogenic brain. To investi-
gate the effect of truncated α-Syn on the fibril formation
of α-Syn, the fibrillation of a mixture of truncated and
full-length α-Syn was monitored by TfT fluorescence and
light scattering analysis. When truncated α-Syn110 and
α-Syn119 coexisted with full-length α-Syn at a ratio of 1:1,
the fibrillation rate increased and the lag time for fibrilla-
tion was reduced significantly, compared with those of
full-length α-Syn ((Fig. 2) and Table 1).
Also, we performed the experiments to show the effect
of truncated α-Syn with full length one. In order to show
that the presence of truncated α-Syn enhances the fibril
formation of α-Syn, various samples with different ratio
of full length and α-Syn119 were prepared, fixing the final
molar ratio at 70 μM α-Syn. If the presence of truncated
α-Syn enhances the fibril formation of α-Syns, the
amount of fibril should be higher than the sum of the
amount of fibril formed with each α-Syn sample with
each concentration. We used the amount of amyloid after
80 hours of incubation of the sample with 70 μM full
length α-Syn alone as the control (100%). While the sam-
ple containing 35 μM of α-Syn119 alone resulted 120% of
Figure 2 Fibril formation of C-terminal-truncated variants and the mixture with full-length α-synuclein. The time course of fibril formation was 
obtained from the TfT fluorescence assay analysis. Seventy μM protein was incubated in triplicate in PBS buffer with 0.02% NaN3, pH 7.4. Full-length 
α-Syn (white squares), α-Syn110 (white triangles), α-Syn119 (white circles), α-Syn133 (white diamonds), and 35 μM full-length α-Syn + either 35 μM α-
Syn110 (black triangles) or 35 μM α-Syn19 (black circles) or 35 μM α-Syn133 (black diamonds).
Figure 3 Aggregation of C-terminal truncated α-synuclein. Full-
length α-Syn (70 μM) and truncated variants (70 μM) were incubated 
in PBS buffer, pH 7.4 with stirring at 37°C in the absence (white bar) or 
presence of 280 μM PQQ (black bar). Usually, the formation of total ag-
gregations is monitored at 330 nm. However, PQQ has a typical absor-
bance at around 340 nm; so, the light scattering was monitored at 500 
nm. n = 3 and error bar = standard deviation.
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α-Syn119 (total 70 μM) resulted 450% compared with the
sample containing 70 μM of full length α-Syn.
The observed amyloid formation was not the simple
sum of the expected amount of amyloid forming from
each α-Syn. The experiments were carried out with dif-
ferent mixing ratio, and similarly, the amount of fibril
estimated from TfT fluorescence was not the simple sum
and higher than those from the each α-Syn samples (Fig.
4). It is obvious that co-existence of full length α-Syn and
truncated synuclein enhanced the total fibril formation of
α-Syns. The presence of α-Syn110 also enhanced the total
amyloid formation of α-Syn, but the effect was weaker
than α-Syn119. However, truncated α-Syn133 has no
effect on fibrillation of α-Syn.
The light-scattering assay showed that the aggregation
of full-length of α-Syn was increased 3-fold by mixing
with α-Syn110. When α-Syn119 was mixed with full-
length α-Syn, the OD500 was slightly increased (Fig. 5).
But α-Syn133 did not enhance the aggregation of full-
length α-Syn. It indicated that α-Syn110 and α-Syn119
enhanced the aggregation of full-length α-Syn, but not α-
Syn133.
PQQ prevents the fibril formation of truncated α-synuclein
We have previously reported that PQQ prevents the
aggregation and fibril formation of full-length α-Syn, and
here we investigated whether or not PQQ also prevents
the fibril formation of truncated α-Syn. It has been
reported, in agreement with this study, that C-terminal
truncation accelerates α-Syn fibril and oligomer forma-
tion. Also, truncated α-Syn promotes the fibril formation
of full-length α-Syn. However, the presence of PQQ in
truncated α-Syn solutions resulted in the dramatic pre-
Table 1: The kinetic analysis of α-Syn variants in this study.
Lag-time (h) Full-length α-Syn α-Syn110 α-Syn119 α-Syn133
α-Syn (70 μM) 21.4 4.8 14.3 36.1
Truncated α-Syn (35 μM) 
+
Full-length α-Syn (35 μM)
- 5.0 8.8 31.4
α-Syn (70 μM) +
PQQ (280 μM)
30.5 8.6 23.5 47.7
The lag time analysis of fibril formation was calculated from fitting-curve of TfT fluorescence was provided by PRISM (GraphPad Software)
Figure 4 Impact of C-terminal-truncated α-synuclein on the amy-
loid formation of full length of α-synuclein. It showed the amount 
of amyloid after 80 hours of incubation of the sample with 70 μM full 
length α-Syn alone as the control (100%, white bar). 35, 14, and 7 μM 
of α-Syn119 and 35 μM of α-Syn110 (black bar) and the mixture protein 
(35 μM full-length α-Syn + 35 μM α-Syn119, 56 μM full-length α-Syn + 
14 μM α-Syn119, 63 μM full-length α-Syn + 7 μM α-Syn119 and 35 μM 
full-length α-Syn + 35 μM α-Syn110, gray bar) was incubated in tripli-
cate in PBS buffer with 0.02% NaN3, pH 7.4. The fibril formation was ob-
tained from the TfT fluorescence assay analysis.
Figure 5 Impact of C-terminal-truncated α-synuclein on the ag-
gregation of full length of α-synuclein. 70 μM full-length α-Syn, 35 
μM truncated variants or a mixture of 35 μM full-length α-Syn and 35 
μM truncated variants (Syn110+WT, Syn119+WT, Syn133+WT) were in-
cubated in PBS buffer, pH 7.4, with stirring at 37°C in the absence 
(white bar or gray bar) and presence of 280 μM PQQ (black bar). The 
light scattering at 500 nm was used to monitor the total aggregation. 
n = 3 and error bar = standard deviation.
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addition of 280 μM PQQ, the fibrils formed in 70 μM
truncated α-Syn110, α-Syn119, and α-Syn133 decreased
to less than 50, 27, and 14.8% of the fibrils formed in the
absence of PQQ, respectively. The higher the concentra-
tion of PQQ, the less truncated α-Syn fibrils were formed
(Fig. 7). This indicates that the inhibitory effect is PQQ-
dose-dependent. In addition, fibril formation in the mix-
ture of truncated and full-length α-Syn was markedly
inhibited (Fig. 8). In the presence of PQQ, moreover, the
light scattering did not increase significantly, indicating
that PQQ prevents the formation of truncated α-Syn
aggregates ((Fig. 3) and (Fig. 5)). These results indicate
that PQQ prevents the amyloid fibril formation and
aggregation of truncated α-Syn as well as full-length α-
Syn in a PQQ-concentration-dependent manner.
PQQ decreases the cytotoxicity of truncated α-synuclein
Previous studies have shown that aggregation and fibrilli-
zation of amyloid protein is toxic to neural cells
[10,12,29,30]. We evaluated the effect of PQQ on the
cytotoxicity of truncated variants to cultured PC12 cells.
PC12 is a rat kidney cell line frequently used in the study
of normally developing nervous systems. Full-length and
truncated α-Syn samples were added to PC12 cells and
incubated in the presence or absence of PQQ. These sam-
ples were then further cultured for four days with shaking
at 37°C. We then evaluated the cytotoxicity of full-length
and truncated α-Syn by adenylate kinase assay (AK assay),
which measures quantitatively the release of AK from the
damaged cells. The released AK converts ADP to ATP,
which is measured by the bioluminescence assay, thus
allowing the accurate and sensitive determination of
cytotoxicity. Upon incubation of PC12 cells with 14 μM
α-Syns (full-length αSyn, α-Syn110, α-Syn119, and α-
Syn133), the bioluminescence increased to 1500, 3600,
28200, and 7300 RLUs, respectively. This indicates that
the C-terminal-truncated α-Syn is highly toxic to PC12
cells, as opposed to the full-length α-Syn (Fig. 9). Addi-
tion of 28 μM α-Syn results in 1.4- to 1.8-fold higher bio-
luminescence than with 14 μM α-Syn, indicating that the
cytotoxicity truncated α-Syn is dose-dependent.
The cytotoxicity evaluation results of α-Syn119 based
on MTT assay are in good agreement with those from the
Figure 6 Inhibition of the amyloid fibril formation of C-terminal-
truncated α-synuclein by PQQ. Full-length α-Syn (70 μM) and trun-
cated variants (70 μM) were incubated in PBS buffer, pH 7.4 with stir-
ring at 37°C in the absence (white bar) or presence of 280 μM PQQ 
(black bar). Fibril formation was measured by TfT fluorescence. n = 3 
and error bar = standard deviation.
Figure 7 The inhibitory effect of PQQ on the fibril formation of 
full-length or C-terminal-truncated α-synuclein at several con-
centrations. Full-length α-Syn (white squares), truncated α-Syn119 
(white circles) and truncated α-Syn110 (white triangles).
Figure 8 Inhibition by PQQ of the amyloid fibril formation of C-
terminal-truncated α-synuclein mixed with full-length α-synucle-
in. 70 μM full-length α-Syn or a mixture of 35 μM full-length α-Syn and 
35 μM truncated variants was incubated in PBS buffer, pH 7.4 with stir-
ring at 37°C in the absence (white bar or gray bar) and in the presence 
of 280 μM PQQ (black bar). Fibril formation was measured by TfT fluo-
rescence.
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wild-type, full-length α-Syn (Fig. 10). However, surpris-
ingly, when PC12 cells to which truncated α-Syn was
added were incubated with 200 μM PQQ, the biolumi-
nescence decreased to 30-70% of that of the samples not
treated with PQQ. The significant decrease in release of
AK from damaged cells, suggests that the presence of
PQQ greatly decreases the cytotoxicity of truncated α-
Syn.
Recent studies have suggested that the oligomeric inter-
mediate of fibrillation has a higher toxicity than the fibril.
For the therapeutic application of PQQ, it is therefore
important to investigate the effect of PQQ on both the
oligomer formation and cytotoxicity of truncated α-Syn.
We investigated the formation of oligomers of truncated
synuclein119 with and without PQQ by dot blotting anal-
ysis using the anti-oligomer-specific antibody A11 [31].
We incubated 200 μM truncated synuclein119 in the
absence or presence of a four-fold molar excess of PQQ
and sampled at several times. In the absence of PQQ, the
staining intensity of the α-Syn119 increased during the
12-hour time course (Fig. 11), reflecting the accumulation
of oligomer. In contrast, the amount of oligomer did not
change in the presence of PQQ. The cytotoxicity of these
incubated samples, measured by adding them to U2-OS
cells and culturing for 24 hours, increased in an oligomer
dose-dependent manner. In the presence of PQQ, the
cytotoxicity of a 12-hour incubated α-Syn119 was only
Figure 9 C-terminal-truncated α-synuclein-mediated cytotoxici-
ty can be mitigated by PQQ. Full-length α-Syn and truncated α-Syn 
(final concentration 14 or 28 μM) were added to PC12 cells with shak-
ing at 37°C in the absence or presence of 200 μM PQQ. After 96 h of in-
cubation, the release of adenylate kinase from the damaged cells was 
measured by the luminescence of luciferase. n = 3 and error bar = stan-
dard deviation.
Figure 10 C-terminal-truncation enhanced the cytotoxicity of α-
synuclein. Percentage of cell viability of PC12 cells added 21 μM of 
fresh or incubated α-Syn from n = 3 independent experiments. The re-
sults are expressed as a percentage of the value of "control" (PBS) (gray 
bar), which is set as 100%. Values are expressed as mean ± SD. Full-
length α-Syn (white bar), and α-Syn119 (black bar).
Figure 11 Formation of C-terminal-truncated α-synuclein oli-
gomer can be reduced by PQQ. The dot blot analysis of truncated α-
Syn119 sample with or without PQQ using anti-oligomer antibody, 
A11. 0 ~ 12 h incubated α-Syn119 was stained in membrane. Same 
samples were used to cell viability assay. 21 μM of incubated α-Syn119 
in several time added to U2-OS cells. The results are expressed as a per-
centage of the value of "control" (PBS) (white bar), which is set as 100%. 
Values are expressed as mean ± SD, n = 3. Truncated α-Syn119 alone 
(white bar), and α-Syn119 + PQQ (black bar).
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incubated 12 hours without PQQ. This clearly indicates
that the cytotoxicity of α-Syn is related the oligomer for-
mation by the truncated α-Syn119, and PQQ prevents the
cytotoxicity of truncated α-Syn119 by inhibiting the for-
mation of oligomers.
Discussion
In this work, we prepared recombinant truncated α-
Syn110, α-Syn119, and α-Syn133 and investigated the
aggregation and fibril formation of these proteins in vitro.
Also, we investigated the inhibitory effect of PQQ on the
fibril formation and cytotoxicity of C-terminal-truncated
α-Syn. It is the first attempt to characterize the aggrega-
tion and fibril formation of α-Syn119 and α-Syn133. It is
possible that these truncated α-Syn variants play an
important role in the pathogenesis of PD and related dis-
eases, because C-terminal-truncated α-Syn119 and α-
Syn133 have been found in both the normal and the
pathogenic brain [18]. It is commonly understood that
rapid aggregation and fibril formation occurs upon the
truncation of the acidic C-terminal of α-Syn, which con-
tains 10 glutamates and 5 aspartates. By truncation of
negative charge acids, the repulsion between C-terminals
of α-Syn was decreased and the possibility of interaction
between hydrophobic regions contained NAC was
increased. As a result, the aggregation and/or fibril for-
mation were accelerated. In fact, α-Syn110 and α-Syn119
did show high aggregation and fibrillization speeds and
rates compared to full-length α-Syn in our present study.
Unexpectedly the result of TfT fluorescence assay indi-
cated that α-Syn133 slowed down the fibrillation in com-
parison with full-length α-Syn, whereas, α-Syn133 has
almost equivalent aggregation with full-length α-Syn was
observed. We understood that the speed of fibril forma-
tion of α-Syn133 decreased whereas the final quantity of
fibril and aggregates are in the same level as those for wild
type. Considering that the fibril elongation process is
influenced by the status of soluble oligomers, the
decreased kinetics in fibril formation of α-Syn133 might
suggest the change of oligomeric status of α-Syn133.
Some studies have investigated the C-terminal-trun-
cated α-Syn seeding mechanism, in which the truncated
fragments nucleate full-length α-Syn aggregation through
the formation of hybrid protofibrils and then fibrils
[17,20,32,33]. This shortens the lag-time of fibril forma-
tion. When truncated α-Syn110 and α-Syn119, but not α-
Syn133, coexisted with full-length α-Syn, it dramatically
enhanced the total fibril formation of α-Syn. It indicated
that co-existence of full length and truncated
synuclein119 have synergistic effect on aggregation and
fibrillation. Alzheimer's disease results mainly from the
accumulation of amyloid β (1-42), though the total
amount is lower than that of amyloid β (1-40). Likewise, it
is presumed that the induction of the aggregation of full-
length α-Syn by a small amount of C-terminal-truncated
α-Syn is critical to its pathogenesis. Therefore, it is
important to develop an inhibitor for the aggregation and
fibrillization of truncated forms of α-Syn as well as full-
length α-Syn.
PQQ exists in several plants and animals, and has been
drawing attention as a novel nutritional factor due to its
positive effect on cellular growth and its potential as a key
pharmacological compound. Pharmacological research
has addressed the issue of PQQ as a potential antioxidant
and redox modulator. We have previously reported that
PQQ prevents the fibril formation of full-length α-Syn
and also influences the conformational change of α-Syn
[28].
In our present study, PQQ significantly decreased the
aggregation and fibril formation of truncated α-Syn as
well as full-length α-Syn. Furthermore, in the presence of
PQQ, aggregation and fibril formation in mixtures of C-
terminal-truncated and full-length α-Syn were inhibited.
This is the first report of an inhibitor for the aggregation
and fibril formation of C-terminal-truncated α-Syn. In
the presence of 4-fold molar PQQ, the fibril formation of
full-length α-Syn and α-Syn133 was prevented to 10% of
the fibrils formed in the absence of PQQ. However, in the
case of α-Syn110 with 4-fold molar PQQ, fibril formation
decreased only by 50%. The fibril formation of α-Syn119
decreased to 30% under the conditions of the experiment,
as monitored by TfT fluorescence assay. This indicates
that PQQ inhibits fibrillization in all of these C-terminal-
truncated α-Syns, but that the potency of its inhibitory
activity is different in each case (Fig. 7).
We have previously reported on the UV spectrum of α-
Syn incubated with PQQ, which showed remarkable dif-
ferences from the typical absorbance of PQQ or α-Syn
alone. This suggests that PQQ forms a conjugate with α-
Syn and that PQQ has reactive quinone groups, just as
the oxidized form of baicalein [23]. Therefore, it is highly
probable that PQQ binds with α-Syn via a Schiff base.
Likewise, it is conceivable that PQQ binds to C-terminal-
truncated α-Syn via a Lys residue. Although the number
of Lys residues in C-terminal-truncated α-Syn is equal to
that in full-length α-Syn, the inhibitory effect of PQQ is
different between full-length α-Syn and truncated α-Syn.
Based on the results of the TfT fluorescence assay, it is
considered that the difference in the efficacy of PQQ's
inhibitory activity derives from the speed of aggregation
and fibrillization of each variant of truncated α-Syn. Since
the aggregation and fibril formation of truncated α-Syn is
faster than those of full-length α-Syn, in the case of trun-
cated α-Syn, the reaction rate of binding with PQQ may
be lower. As a result, until fibril formation begins, the
instances of PQQ binding with truncated α-Syn will be
fewer than with full-length α-Syn. We have reported that
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fibril formation [28]. This "feedback effect" gives PQQ
considerable leverage in its inhibition of full-length α-Syn
aggregation. In the case of C-terminal-truncated α-Syn,
however, the effect is reduced by the ever decreasing
quantity of PQQ-conjugated α-Syn.
It was known that amyloid proteins are toxic to culture
cell and the expression of amyloid proteins was induced
the damage of neurons in many neurodegeneration mod-
els. It is therefore important to evaluate the effect of PQQ
on the cytotoxicity of amyloid proteins to develop an ade-
quate therapy strategy. In this study, we measured the
cytotoxicity of C-terminal-truncated α-Syn by adenylate
kinase assay, MTT and ATP assay. The results show that
C-terminal-truncated α-Syn was much more toxic to
PC12 cells in a dose-dependent manner than full-length
α-Syn. Especially the cytotoxicity of truncated α-Syn119
was distinctly different from that of other α-Syn variants.
Under the experimental conditions, the luminescence
intensity was 20-fold higher than that of full-length α-
Syn. Interestingly truncated α-Syn133 is more toxic to
PC12 cells than full-length α-Syn and α-Syn110. As we
mentioned above, the decreased kinetics in fibril forma-
tion of α-Syn133 might suggest the change of oligomeric
status of α-Syn133. In this respect, our interpretation that
the increased toxicity of α-Syn133 owes to the change in
the oligomeric status is in consistent with the experimen-
tal observation. We believe that truncation of the seven
C-terminal residues affected the oligomeric status, conse-
quently change the fibrillation kinetics.
Recently some studies suggested the intermediate of
fibrillation, oligomer, has a high toxicity than fibril. It was
known that some inhibitor of α-Syn aggregation
increased the cytotoxicity of α-Syn despite the aggrega-
tion and fibril formation was significantly decreased [11].
These reports suggested that inhibitors induced the sta-
ble state of oligomer, intermediate of aggregation, and
increased the cytotoxicity more. Other studies showed
cytotoxicity of amyloid proteins was dependent on the
conformations of oligomers as followed references
[34,35], not the property of fibrillation. Thus, these stud-
ies supported that the fibrillation tendency of each vari-
ant dose not directly correlate their cytotoxicity effects.
We showed that formed oligomer of truncated α-Syn119
was related to cytotoxicity of α-Syn and PQQ could
inhibit the cytotoxicity of truncated synuclein119 by pre-
venting the oligomer formation. In the progress of fibril
formation, oligomerization is essential step for the fibril-
lation. From the results of kinetics of truncated synuclein
in the presence of PQQ, the lag-time of fibrillation was
delayed by PQQ which means that the formation of seeds
for elongation of fibril, were prevented by PQQ. Together
with results of cytotoxicity, it suggested that PQQ also
could decrease the formation of truncated synuclein oli-
gomers. This suggests that PQQ is a strong candidate for
future anti-PD reagent compounds.
Conclusions
Here, we showed that α-Syn110 and α-Syn119 has a high
propensity of aggregation and enhanced the fibrillation of
α-Syn. Although both of α-Syn119 and α-Syn133 showed
a high cytotoxicity to culture cell, α-Syn133 showed a
similar aggregation with full-length α-Syn and no acceler-
ation effect. PQQ dramatically inhibits fibril formation in
C-terminal-truncated α-Syn, as well as in mixtures of
full-length α-Syn with truncated variants. Moreover,
PQQ decreases the cytotoxicity of truncated α-Syn.
Together with other findings on the inhibitors of amyloid
proteins, this suggests that inhibitors other than PQQ,
which also bind to target proteins, could prevent the
aggregation and fibrillation of truncated α-Syn in a simi-
lar manner. In any case, PQQ is a strong candidate for a




Thioflavin T (TfT) was purchased from Sigma. Pyrrolo-
quinoline quinone was kindly donated by Mitsubishi Gas
Chemical Company, Inc.
Recombinant DNA technology
The full-length α-Syn structural gene was subcloned into
the pET-28a(+) vector (Novagen). To construct the
expression vectors of C-terminal-truncated α-Syn, pET-
28a(+)-α-Syn vector was used to carry out site-directed
mutagenesis using a QuikChange® Site-Directed Muta-
genesis Kit (Stratagene) with the following oligonucle-
otides inserted as the stop codon: 5'-GAAGGAGC
CCCACAGGAATAAATTCTGGAAGATATGCCTGT
G-3' (truncated α-Syn110), 5'-CTGGAAGATATG CCT-
GTGGATTAAGACAATGAGGCTTATGAAATGC CT-
3' (truncated α-Syn119) and 5'-CCTTCTGAGGAAGGG-
TATTAAGACTACGAACCTGAA-3' (truncated α-
Syn133). The sequence of the inserted gene fragment was
confirmed by automated DNA sequencing (PerkinElmer
ABI Model 310).
Expression vectors containing full-length α-Syn and
truncated variants were thus constructed. The proteins
used in this study were expressed in Escherichia coli BL21
(DE3). α-Syn expression was induced by the addition of
0.3 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG).
The cells were disrupted using a French press (Ohtake
Works, Inc.), and the supernatant was collected by cen-
trifugation (18,500 g, 10 min, 4°C). After boiling the col-
lected supernatant at 100°C for 20 min, it was centrifuged
(18,500 g, 10 min, 4°C) and dialyzed against buffer A (20
mM Tris-HCl, pH 8.0). After further centrifugation
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Page 9 of 11(12,000 g, 20 min, 4°C), the supernatant was loaded onto a
Resource Q column (for full length α-Syn, truncated α-
Syn119 and α-Syn133) or a Resource S column (for trun-
cated α-Syn110) (GE Healthcare Bio-Science Corp.) and
eluted with a 0-0.5 M NaCl gradient in buffer A. The
eluted fractions were analyzed by SDS-PAGE, and the
fractions containing α-Syn were dialyzed against PBS buf-
fer (8.1 mM Na2HPO4, 1.4 mM KH2PO4, 137 mM NaCl
and 2.7 mM KCl, pH 7.3). The concentrations of the pro-
teins were determined by means of a DC protein assay kit
(Bio-Rad).
Preparation of aggregated solutions and TfT fluorescence & 
light-scattering assay
Purified α-Syn was concentrated to ca. 3.0 mg/ml using
Amicon Ultra-15 filters (Millipore) in PBS buffer, pH 7.3,
centrifuged (150,000 g, 1 h, 4°C) to remove any aggre-
gates, and adjusted to 2.0 mg/ml. PQQ was dissolved in
the same buffer at the defined concentration. The reac-
tion solution contained 70 μM full-length or truncated α-
Syn in the presence or absence of PQQ. Mixtures of full-
length α-Syn and truncated α-Syn with or without 280
μM PQQ were also prepared. These samples were incu-
bated on a 96-well plate in 200 μl of PBS buffer, pH 7.3,
with 0.02% NaN3 at 37°C with shaking at 700 rpm. Fibril
formation was monitored by thioflavin T (TfT) fluores-
cence. Aliquots of 5 μl were removed from the incubated
samples and added to 250 μl of 25 μM TfT in PBS buffer,
pH 7.3. TfT fluorescence was recorded at 486 nm with
excitation at 450 nm using an ARVO MX 1420 multilabel
counter (PerkinElmer). The lag time analysis of fibril for-
mation was calculated from fitting-curve of ThT fluores-
cence was performed by PRISM (GraphPad Software). To
compare the total aggregation of full-length and trun-
cated α-Syn, the light scattering was studied. After incu-
bation, 60-μM samples were measured at 500 nm.
Usually, the formation of aggregations is monitored at
330 nm. However, PQQ has a typical absorbance at
around 340 nm; so, the light scattering was monitored at
500 nm
Cell culture and cytotoxicity analyses of truncated α-
synuclein
PC12 cells (ATCC CRL1721) were routinely cultured in
RPMI-1640 medium (Sigma) containing 5% fetal calf
serum, 10% horse serum and 1% penicillin-streptomycin,
and maintained at 37°C in a humidified incubator with
5% CO2/95% room air. For the cytotoxicity studies, the
medium was removed and fresh medium was gently
added before plating.
The cytotoxicity was measured by adenylate kinase
assay. In brief, PC12 cells were plated at a density of
10,000 cells per well on CC3-coated 96-well plates (Nunc)
in 100 μl of Opti-MEM medium. After 24 h of incubation,
full-length or truncated α-Syn was added at the indicated
concentration, and 200 μM PQQ was also added in half of
the wells. The cells were incubated for an additional 4
days with shaking at 500 rpm, 37°C. The release of adeny-
late kinase from the damaged cells was measured using a
ToxiLight® Bioassay Kit obtained from LONZA [36,37].
Fifty μl of culture medium were removed from the each
well and added to 100 μl of the reaction substrate. After
incubation at room temperature for 5 min, the lumines-
cence was measured on an ARVO MX 1420 multilabel
counter (PerkinElmer). The bioluminescence of the con-
trol cells treated with PBS or PQQ instead α-Syn was also
measured in the same way. PQQ had no effect on the AK
assay as the luminescence with PBS was identical to that
with PBS plus PQQ. The results shown in (Fig. 9) are after
subtraction of these background values.
The cytotoxicity was measured by MTT and ATP assay.
In brief, PC12 or U2-OS cells were plated at a density of
10000 cells per well on CC3-coated 96-well plates in 100
μl of fresh medium. After 24 h of incubation, full-length
or truncated α-Syn119 was added at final concentration
of 20 μM and cells were incubated for an additional 24 h.
In MTT assay, cellular redox activity of tetrazolium for-
mazan, 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-
5-(2,4-disulfophenyl)-2H tetrazolium were measured Cell
Counting Kit-8 (DOJINDO) [38]. After replacement to
fresh medium, 10 μl of stock WST-8 was added and the
incubation was continued for another 2~3 h. Absorbance
values at 450 nm were determined with an ARVO MX
1420 multilabel counter. The absorbance of the cells
treated with PBS instead α-Syn was also measured in the
same way as control (100%). In ATP assay, cell viability
was measured by CellTiter-Glo Luminescent Cell Viabil-
ity Assay Kit (Promega) following the manual. After
replacement to 100 μl fresh medium, 100 μl of stock solu-
tion was added and the incubation was continued for 5
min. The luminescence values were determined with an
ARVO MX 1420 multilabel counter. The luminescence of
the cells treated with PBS instead α-Syn was also mea-
sured in the same way as control (100%).
Dot blot analysis
Purified α-Syn119 was concentrated using Amicon Ultra-
15 filters (Millipore) in PBS buffer, pH 7.3, centrifuged
(150,000 g, 1 h, 4°C) to remove any aggregates, and
adjusted to 3.0 mg/ml in the absence or presence of 800
μM PQQ. These samples were incubated in a 2 ml tube,
in 1.2 ml of PBS buffer, pH 7.3, at 37°C with shaking at
700 rpm. The incubated α-Syn119 was sampled in several
times. 1 μl of each sample applied to a nitrocellulose
membrane, blocked with 10% skim milk in PBS contain-
ing 0.01% Tween 20 (TBS), at room temperature for 1 h,
washed three times for 5 min each with TBS and incu-
bated for 1 hr at room temperature with the anti-oli-
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Page 10 of 11gomer antibody A11 (0.1 μg/ml in TBS). The membranes
were washed three times for 5 min each with TBS, incu-
bated with anti-rabbit IgG diluted 1:10,000 in TBS and
incubated for 1 hour at room temperature. The blots
were washed three times with TBS and developed with
ECL chemiluminescence kit from Amersham-Pharmacia
(Piscataway, NJ).
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